Abstract: Development of the dog superficial retinal vasculature is similar to the mechanism of human retinal vasculature development; they both develop by vasculogenesis, differentiation, and assembly of vascular precursors called angioblasts. Canine oxygen-induced retinopathy (OIR) was first developed by Arnall Patz in an effort to experimentally determine the effects of hyperoxia on the development of the retinal vasculature. The canine OIR model has many characteristics in common with human retinopathy of prematurity. Exposure of 1-day-old dogs to hyperoxia for 4 days causes a vaso-obliteration throughout the retina. Vasoproliferation, after the animals have returned to room air, is robust. The initial small preretinal neovascular formations anastomose to form large preretinal membranes that eventually cause tractional retinal folds. The end-stage pathology of the canine model is similar to stage IV human retinopathy of prematurity. Therefore, canine OIR is an excellent forum to evaluate the response to drugs targeting VEGF and its receptors. Evaluation of an antibody to VEGF-R2 and the VEGF-Trap demonstrated that doses should be titered down so that preretinal neovascularization is inhibited but retinal revascularization is able to proceed, vascularizing peripheral retina and preventing it from being a source of VEGF.
Introduction
Human retinopathy of prematurity (ROP) results when the developing retinal vasculature in the premature infant is exposed to higher-than normal oxygen levels (hyperoxia). Hyperoxia causes development of the retinal vasculature to cease and vaso-obliteration to occur. As the neural retina continues to develop and consumes greater levels of oxygen, the retina becomes hypoxic due to an attenuated retinal vasculature. The resultant hypoxia causes increased levels of hypoxia inducible factor (HIF) and subsequent increased expression of HIF-inducible angiogenic factors like VEGF cause the vasoproliferative stage in ROP. Oxygen-induced retinopathies (OIRs) are animal models for human ROP. None of the models exactly replicates human ROP, but each has some pathological characteristics that mimic the human disease. Canine OIR was first developed by Arnall Patz in an effort to experimentally determine the effects of hyperoxia on the developing retinal vasculature 1, 2 and modified by Flower et al. 3 Dogs are similar to humans in regards to the mechanism of retinal vascular development, and also the end-stage pathology of the canine model is similar to stage IV human ROP having tractional retinal folds in retina. 
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Mcleod and lutty canine retinal vasculature forms by vasculogenesis Unlike rodents, the superficial retinal vasculature of the dog develops by vasculogenesis and not angiogenesis. Vasculogenesis is the development of blood vessels by differentiation, aggregation, and assembly of vascular precursors or angioblasts (Figure 1 ). This process is occurring at birth in dogs and begins in humans at around 14 weeks gestation. [4] [5] [6] The canine retina is only 60% vascularized at birth and angioblasts (positive for adenosine diphosphatase [ADPase] enzyme activity) are present throughout avascular peripheral retina at this time. 4, 7 The initial assembly of the angioblasts results in cords and then lumen develop within the cords. In dogs and humans, astrocyte (the inner retinal glia) differentiation trails vascular development and guidance is provided by Muller glia not astrocytes, unlike neonatal rodent retinas. [5] [6] [7] The Muller cells, which span the retina from internal to external limiting membrane, form glycosaminoglycan-rich extracellular spaces in which vasculogenesis occurs 4 while also providing adenosine via the enzyme 5′ nucleotidase to stimulate the vasculogenic process. 7 Vascular endothelial cell markers (CD34 and von Willebrand's factor) are not expressed in angioblasts and are expressed only in endothelial cells after lumen formation and presumably the presence of serum within the lumens.
canine model of oxygen-induced retinopathy
Newborn dogs are placed into 100% oxygen for 4 days to induce retinopathy. This exposure to hyperoxia arrests the development of the superficial retinal vasculature and causes the vaso-obliterative phase of OIR ( Figure 2 ). This results in 60% loss in vascular area and the vaso-obliteration is the greatest in the capillaries, whereas large blood vessels appear viable as determined by ADPase activity (Figure 3) . 8 The vasoobliteration occurs throughout the retina but islands of surviving endothelial cells can be found throughout the once-vascularized areas ( Figure 3 ). The loss of vasculature in the presence of a differentiating neuroblastic layer (neuronal progenitors) after removal from hyperoxia results in extreme hypoxia, the initiating event in the vaso-proliferative stage in canine OIR.
Revascularization of retina occurs in a burst of disorganized angiogenesis that results in a very dense capillary network in the inner retina (Figure 4) . 9 The extracellular spaces created by Muller cell processes are filled with proliferating astrocytes, and multiple layers of capillaries form the inner retina. At the periphery of the surviving retinal vasculature, glial proliferation occurs resulting in gliosis; in humans, gliosis causes the formation of a ridge of tissue between vascularized and nonvascularized retina, but no anatomical ridge occurs in dogs. 10 By postnatal day 15 (P15), tufts of neovascularization can be seen in vitreous with fundus and red free photography ( Figure 5 ). 9 Vitreous, the gel in posterior chamber of the eye, normally has had regression of the fetal vasculature occur by this time and is becoming avascular. Fluorescein angiography demonstrates the leaky nature of these formations and the extreme tortuosity of arteries ( Figure 5 ). 11 In cross sections, 
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a canine model for human rOP the dense cellularity of these preretinal formations is apparent. Often adjacent tufts of neovascularization will anastomose with each other forming a vascular complex ( Figure 6 ). Eventually the complexes will anastomose forming a dense matlike structure of new blood vessels, which expands to form an extensive preretinal vascular membrane ( Figure 6 ). 12 The membranes, when visualized with fundus photography and fluorescein angiography at P22, appear at times to cover an entire vascular arcade (Figure 7) . 11 The preretinal membranes persist at least until P45 (Figure 8 ) when they appear as tented membranes putting tractional force on the retinas. The result is tractional retinal folds in retina at P45 (Figure 8 ) similar to those formed in stage IV human ROP.
anti-VEgF therapy evaluation in the canine Oir model
In all of the OIR models, VEGF plays a key role in vasculogenic and angiogenic processes in retina.
12-14 VEGF expression is upregulated in retina during development because there is no retinal vasculature and neurons have become metabolically active, consuming the oxygen that is available. In the dog retina, VEGF receptor-2 (VEGFR2 or kinase domain receptor [KDR] ) is present on angioblasts and endothelial cells during development. 14 However, this receptor is greatly upregulated in vasoproliferative stage of OIR in forming intra-retinal as well as extra-retinal neovascularization ( Figure 9 ). 14 The effects of neutralization of VEGFR2 in the canine OIR model was evaluated by implanting ELVAX slow-release polymer pellets (Elvax 40; Aldrich Chemical, Milwaukee, WI) with 300 µg of anti-VEGFR2 (ImClone Systems, New York City, NY, USA) or control non-immune immunoglobulin in the vitreous at P6, 1 day after the removal of the animals from hyperoxia.
14 The animals were sacrificed at P21 and vitreous as well as retinas were incubated for ADPase activity. Anti-VEGFR2 inhibited the formation of preretinal neovascularization, which 
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Mcleod and lutty remains attached to the vitreous body in dog ( Figure 10 ). 14 However, anti-VEGFR2 also inhibited the revascularization of retina compared to control IgG, resulting in a reduced retinal vasculature present only in central retina ( Figure 10) . Analysis of the area of retinal vasculature demonstrated a significant reduction in retinal vasculature in anti-VEGFR2-implanted eyes (Figure 11) . Similarly, the reduction in the area of neovascularization in vitreous was significant in anti-VEGFR2 eyes compared to IgG control eyes; therefore, anti-VEGFR2 at the doses used inhibits the formation of preretinal neovascularization as well as revascularization of inner retina.
The effect of VEGF neutralization in canine OIR model was evaluated using the VEGF-Trap (Aflibercept, Regeneron, Tarrytown, NY, USA).The VEGF-Trap is a recombinant fusion protein invented by Regeneron that has the binding sites for VEGF-R1 and -R2 fused with the fragment, crystallizable (Fc) portion of human IgG1. A single 5, 25, or 250 µg dose of VEGF-Trap in 50 µL was injected into the vitreous at P7. Human Fc at the same doses was injected into control eyes. The effects of these reagents were evaluated at P21 by incubating both the vitreous and the retina for ADPase activity. All doses of VEGF-Trap resulted in the complete prevention of preretinal neovascularization (Figure 12) . 16 The VEGF-Trap also resulted in smaller areas of retinal vasculature at 25 and 250 µg doses ( Figure 13) ; however, the 5 µg trap eyes had normal areas of retinal vasculature ( Figure 13 ). The area of retinal vasculature in 5 µg dose eyes was comparable to control Fc injected eyes, so inner retina could revascularize and reduce hypoxia and VEGF production by retina.
Conclusion
The canine OIR model has many features in common with human ROP. There is profound global vaso-obliteration resulting in the loss of predominantly capillaries and a 50% reduction in vascular density. The neovascularization is robust in retina and in vitreous. The angiogenesis is so exuberant that large membranes can completely cover the retinal vascular arcades. The model is excellent for evaluating antiangiogenic therapies, including targeting VEGF or its receptor, provided that the reagents recognize dog proteins. The newborn dog eye is comparable in size and its vitreous body is comparable in volume to the premature human eye, so preclinical dosing studies are appropriate in canine OIR. Evaluation of reagents targeting VEGFR2 or VEGF in canine model of OIR demonstrates a very important point: preretinal neovascularization must be inhibited without inhibiting revascularization of retina. Therefore, dosing of the reagents is critical and adult human doses are not appropriate for a premature human eye. 17 Avery predicted that 6.5 µg would seem an appropriate dose for a human premature infant eye, which is almost comparable to our 5 ug dose in the canine OIR model, because the premature human eye is slightly larger than neonatal dog model. The goal is to determine a titer that inhibits preretinal neovascularization but permits revascularization of inner retina. The Japanese gardener's philosophy is excellent guidance in dosing: less is more. 
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